Pacific Edge is a New Zealand based biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer.
Two products have recently completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis (CRC). The bladder cancer technology Cxbladder® has been released to the market in Australia and New Zealand. CRC is being readied for commercial release. Pipeline products still in development include gastric and endometrial cancers and melanoma.
Cxbladder® is a non-invasive, accurate test that enables the early detection of bladder cancer from a small volume of urine providing general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy.
The Company is commercialising its products from its new diagnostic laboratory in New Zealand and plans further commercialisation in the US and Europe as a centralised diagnostic service through its own facilities or as a turn-key solution, licensed to selected partners. Pacific Edge has plans for further studies in key markets to engage leading medical and urological opinion leaders who will be vital to success in new markets.